People news: Teva

Share this article:
Teva named former Bristol-Myers Squibb exec Dr. Jeremy Levin to replace Shlomo Yanai, who is retiring from his role as president and CEO of the generics giant in May. Levin joined BMS in 2007 as SVP strategy, alliances and transactions, also managing the company's portfolio of alliances. Before that he served as global head of business development and strategic alliances at Novartis. Yanai, said Teva, is “moving on to a new phase in his career” after five years in the president/CEO role. On his watch, the company went from an $8.4 billion mostly generics business in 2006 to a diversified Pharma with projected 2012 revenue of $22 billion.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in People Moves

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media